CCR2 and rheumatoid arthritis: Our findings support the existence of an immunometabolic signature in RA patients with cardiovascular comorbidity, characterized by CCR2+HLA-DR+ monocytes with enhanced IL-1β/IL-6 production and increased mTORC1 activity.